Humira Market Report: Industry Overview & Future Outlook
Humira (adalimumab) is a medication classified as a tumor necrosis factor (TNF) inhibitor, which works by reducing the inflammatory effects of a specific chemical in the body. It is commonly used to treat various inflammatory conditions in adults, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and hidradenitis suppurativa. In addition to these conditions, Humira is also prescribed for Crohn\'s disease, juvenile idiopathic arthritis, ulcerative colitis, and uveitis in both adults and children.